Gravity's Rainbow

botany, shoes, books, and justice

Erenumab in Phase III clinical trials for episodic migraine

| 0 comments

Erenumab is a fully human monoclonal antibody specifically designed for the prevention of migraine. Erenumab targets and blocks the Calcitonin Gene-Related Peptide (CGRP) receptor, thought to be pivotal in the genesis of migraine. Erenumab is currently being studied in several large global, randomized, double-blind, placebo-controlled trials to assess its safety and efficacy in migraine prevention. [from the press release for the ARISE study]

Kerrie has a nice breakdown of the results, which look quite encouraging, but not magical.

 

Related Posts Plugin for WordPress, Blogger...

I'm listening!

This site uses Akismet to reduce spam. Learn how your comment data is processed.